Douglas Miehm
Stock Analyst at RBC Capital
(2.14)
# 2,764
Out of 4,918 analysts
45
Total ratings
43.59%
Success rate
-3.18%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $8 → $9 | $10.49 | -14.20% | 10 | Aug 1, 2025 | |
| MNKD MannKind | Maintains: Outperform | $10 → $8 | $3.75 | +113.33% | 1 | Jul 23, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $5.71 | +75.13% | 20 | May 2, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $18 → $17 | $13.50 | +25.93% | 13 | Apr 4, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $0.99 | +405.05% | 1 | Mar 10, 2025 |
Aurinia Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $10.49
Upside: -14.20%
MannKind
Jul 23, 2025
Maintains: Outperform
Price Target: $10 → $8
Current: $3.75
Upside: +113.33%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $5.71
Upside: +75.13%
Bausch + Lomb
Apr 4, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $13.50
Upside: +25.93%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $0.99
Upside: +405.05%